HONG KONG, Dec. 22, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," - 801.HK; 910801.TW), China's leading integrated healthcare enterprise, today announced that the Group has further repurchased its shares from the market, accumulating a total of 36,976,000 shares in December 2011, equivalent to 1.81% of the Group's total outstanding shares at a weighted average price of HK$0.83 per share.Mr. KAM Yuen, Chairman and Chief Executive Officer of the Group, reiterated, "The Management believe the Company's current share price do not adequately reflect the true value of the underlying operation. Hence to reciprocate our shareholders, the Company has repurchased its shares from the open market. We will continue to monitor our share price and undertake appropriate actions to repurchase shares when appropriate in consideration to the benefit of our shareholders. On a personal level, my family and I have also been accumulating the Company's shares from the market and now own 21.64% of the Company's shares."
About Golden Meditech Holdings LimitedGolden Meditech Holdings Limited is China's leading integrated-healthcare devices and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.CONTACT:Investor Relations Department Golden Meditech Holdings LimitedAddress:
48/F, Bank of China Tower, 1 Garden Road, Central, Hong KongTel:
+852 3605 8180Fax:
+852 3605 8181Email:
|SOURCE Golden Meditech Holdings Limited|
Copyright©2010 PR Newswire.
All rights reserved